What’s Next for ArQule, Inc. (ARQL) After Today’s Big Increase?

April 17, 2018 - By Ellis Scott

ArQule, Inc. (NASDAQ:ARQL) Logo

The stock of ArQule, Inc. (NASDAQ:ARQL) is a huge mover today! The stock increased 16.67% or $0.45 during the last trading session, reaching $3.15. About 1.86 million shares traded or 165.05% up from the average. ArQule, Inc. (NASDAQ:ARQL) has risen 180.00% since April 17, 2017 and is uptrending. It has outperformed by 168.45% the S&P500.
The move comes after 9 months positive chart setup for the $274.40M company. It was reported on Apr, 17 by Barchart.com. We have $3.31 PT which if reached, will make NASDAQ:ARQL worth $13.72 million more.

Analysts await ArQule, Inc. (NASDAQ:ARQL) to report earnings on May, 2. They expect $-0.06 earnings per share, up 45.45 % or $0.05 from last year’s $-0.11 per share. After $-0.09 actual earnings per share reported by ArQule, Inc. for the previous quarter, Wall Street now forecasts -33.33 % EPS growth.

ArQule, Inc. (NASDAQ:ARQL) Ratings Coverage

Among 5 analysts covering Arqule (NASDAQ:ARQL), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Arqule had 5 analyst reports since December 14, 2017 according to SRatingsIntel. Needham upgraded the stock to “Buy” rating in Thursday, December 14 report. B. Riley & Co maintained the stock with “Buy” rating in Monday, February 12 report. The firm has “Buy” rating by FBR Capital given on Friday, February 2. The stock has “Buy” rating by Leerink Swann on Thursday, April 5.

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company has market cap of $274.40 million. The Company’s lead product candidate is tivantinib , a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer. It currently has negative earnings. The companyÂ’s clinical-stage products include ARQ 087, a multi-kinase inhibitor of the fibroblast growth factor receptor family Phase II clinical trial for patients with intrahepatic cholangiocarcinoma and in Phase Ib for multiple oncology indications; ARQ 092, an inhibitor of the AKT serine/threonine kinase in Phase I clinical trials for multiple oncology indications; ARQ 751, a next-generation inhibitor of AKT in Phase I clinical trial for solid tumors; and ARQ 761, an intravenously administered analogue of Beta-lapachone, which is Phase 1b clinical trial used as a promoter of NQo1-mediated programmed cancer cell death.

ArQule, Inc. (NASDAQ:ARQL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: